ASCETIC

Acinetobacter: A Study of Colonization Emergence and Trans mission in Intensive Care (The ASCETIC Study) 
 

Nosocomial infection with Acinetobacter spp is a significant challenge, particularly in low and middle income countries (LMICs), where it develops 5 times more frequently, and is associated with an attributable mortality of 25%. Acinetobacter is an aquaphilic organism that thrives in wa-ter, and data from some epidemiologic studies have implicated hospital water sources as a reservoir of nosocomial infection. The ASCETIC study seeks to understand the role of modifiable environmental factors in the acquisition of colonization with Acinetobacter

ASCETIC is a collaboration amongst InFACT groups in LMICs—LACCTIN (Giselle Sutton, Jorge Sin-clair, and Sebastian Ugarte), the Chinese Critical Care Clinical Trials Group (Lina Zhang and Du Bin), the Asian Critical Care Trials Group (Jason Phua and Charles Gomersall), South East Asian Research in Criticalcare Health (Madiha Hashmi), and the Acute Care for Africa Research and Training (TBC ) - Canada, (Canadian Critical Care Trials Group, Laura Bosco, Srinivas Murthy, and John Marshall) and Australia (ANZICS CTG, Shay McGuiness and Steve Webb). ASCETIC will serve not only as a large international research collaboration, but as importantly, as a platform for mentorship and education for emerging trials groups. A systemat-ic review of risk factors has been completed, and an international point prevalence study is planned for mid-2016. 

We welcome other participating sites: please contact John Marshall at marshallj@smh.ca. 

 

Executive Members

  • ANZICS Clinical Trials Group
  • BRICNet
  • CCCCTG
  • CCCTG
  • CRISMA
  • ESICM
  • George Institute
  • GiViTI
  • GSA
  • ICNARC
  • ICS UK
  • ICCTG
  • LASI
  • SCCTG-Scottish
  • SCCTG-Scandinavian
  • SEPNET
  • SOAP Investigators
  • USCIITG